BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
BMRN Stock Chart & Stats
$54.53
$0.93(1.37%)
At close: 4:00 PM EST
$54.53
$0.93(1.37%)
Day’s Range― - ―
52-Week Range$50.76 - $66.28
Previous CloseN/A
Volume465.01K
Average Volume (3M)1.87M
Market Cap
$10.49B
Enterprise Value$9.89B
Total Cash (Recent Filing)$1.56B
Total Debt (Recent Filing)$642.87M
Price to Earnings (P/E)32.7
Beta0.48
Next Earnings
Apr 29, 2026EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding192,323,360
10 Day Avg. Volume1,534,256
30 Day Avg. Volume1,871,906
Financial Highlights & Ratios
PEG Ratio-1.71
Price to Book (P/B)1.87
Price to Sales (P/S)3.54
P/FCF Ratio15.72
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.07
Enterprise Value/Gross Profit3.98
Enterprise Value/Ebitda17.25
Forecast
1Y Price Target
$91.14Price Target Upside67.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)4.28
Revenue Forecast (FY)$3.62B
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyClinical trial data showed statistically significant and sustained improvements in body proportionality for achondroplasia patients who began Voxzogo treatment before age two, supporting earlier initiation and clinical differentiation.
Market Penetration UpsideLow current market penetration among eligible achondroplasia patients indicates substantial upside for Voxzogo adoption as awareness and access expand, which could drive revenue growth.
Portfolio DiversificationAcquisition of Amicus expands the enzyme replacement therapy portfolio and reduces exposure to competition for Voxzogo, providing diversification that could support valuation and debt reduction.
Bears Say
Competitive ConvenienceApproval of a once-weekly injectable rival offers a more convenient dosing option than Voxzogo's once-daily injection and could pressure U.S. market share.
Geographic Regulatory RiskHeavy reliance on international sales makes Voxzogo vulnerable to regulatory decisions in Europe, where approval of competing therapies could significantly weaken global revenues.
Safety ConcernsReports of slipped capital femoral epiphysis in investigator-led studies prompted discontinuation of several development programs, creating safety-related uncertainty that could constrain label expansion.
BioMarin Pharmaceutical News
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $50.76 and its highest was $66.28 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $10.49B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Apr 29, 2026 which is in 15 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Feb 23, 2026. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of $0.169 by -$0.409.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.73.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 192,323,360 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of -$0.24 in its last earnings report, missing expectations of $0.169. Following the earnings report the stock price went down -0.477%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Currently, no hedge funds are holding shares in BMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioMarin Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.14 (67.14% Upside)
$91.14 (67.14% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.17%
12-Months-Change
Fundamentals
Return on Equity
5.82%
Trailing 12-Months
Asset Growth
8.66%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
BMRN Company Deck
BMRN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive commercial and operational performance: record revenues, strong YOY growth for Voxzogo and enzyme therapies, improved profitability (non-GAAP EPS and operating cash flow), clear near-term R&D catalysts, and strategic acquisitions that should expand the portfolio and future revenues. Headwinds were acknowledged and quantified — notably the Roctavian withdrawal and related charges, one-time Q4 order timing effects leading to a weaker Q1, lower royalty expectations, routine market-access renegotiations in select countries, and modest near-term dilution and costs tied to the Amicus acquisition. Management provided concrete 2026 guidance (excluding Amicus post-close contributions) and explained assumptions for competitive scenarios. Overall, positives (robust growth, cash generation, pipeline catalysts, and strategic M&A) outweigh the defined near-term and one-time negatives.View all BMRN earnings summariesBMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
BMRN Stock 12 Month Forecast
Average Price Target
$91.14
▲(67.14% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Summit Therapeutics
―
Immunovant
―
Ownership Overview
0.45% Insiders
30.32% Mutual Funds
36.41% Other Institutional Investors
11.62% Public Companies and
Individual Investors